Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Retained Earnings (2019 - 2025)

Silence Therapeutics' Retained Earnings history spans 7 years, with the latest figure at -$3.0 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 99.37% year-over-year to -$3.0 million; the TTM value through Dec 2025 reached -$3.0 million, up 99.37%, while the annual FY2025 figure was -$3.0 million, 99.37% up from the prior year.
  • Retained Earnings for Q4 2025 was -$3.0 million at Silence Therapeutics, up from -$3.1 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$3.0 million in Q4 2025 and bottomed at -$529.8 million in Q2 2025.
  • The 5-year median for Retained Earnings is -$304.7 million (2022), against an average of -$250.7 million.
  • The largest annual shift saw Retained Earnings fell 25.39% in 2024 before it surged 99.37% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$300.6 million in 2021, then fell by 2.74% to -$308.8 million in 2022, then decreased by 22.44% to -$378.1 million in 2023, then decreased by 25.39% to -$474.0 million in 2024, then soared by 99.37% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Retained Earnings are -$3.0 million (Q4 2025), -$3.1 million (Q3 2025), and -$529.8 million (Q2 2025).